First-trimester screening for aneuploidy.
Prenatal screening for aneuploidy in the first trimester using novel ultrasound and maternal serum markers represents a promising improvement over the currently available second-trimester screening methods. This article reviews the current status of first-trimester screening for Down syndrome and other aneuploidies and explores the issues related to implementing first-trimester screening into mainstream prenatal care in the United States.
Brigatti
Karlla W
KW
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, Columbia Presbyterian Medical Center, 622 West 168th Street, PH16, New York, NY 10032, USA.
Malone
Fergal D
FD
D000782:Aneuploidy; D015415:Biomarkers / Q000097:blood; D001783:Blood Flow Velocity; D004314:Down Syndrome / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008099:Liver / Q000098:blood supply / Q000196:embryology; D008403:Mass Screening; D009295:Nasal Bone / Q000196:embryology; D009333:Neck / Q000000981:diagnostic imaging / Q000196:embryology; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011272:Pregnancy, Multiple; D016216:Ultrasonography, Prenatal; D014471:Umbilical Veins / Q000502:physiology; D014682:Vena Cava, Inferior / Q000196:embryology
D015415:Biomarkers